Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
Yehuda HandelsmanChantal MathieuStephano Del PratoEva JohnssonRaisa KurlyandskayaNayyar IqbalRicardo Garcia-SanchezJulio RosenstockPublished in: Diabetes, obesity & metabolism (2019)
Early intensification to triple therapy with DAPA plus SAXA results in better, more durable glycaemic control than addition of SITA only (dual therapy) in patients with high HbA1c levels who are uncontrolled with MET monotherapy.